Cargando…
A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa
BACKGROUND: Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PWID is high. It is almost 84% in Pretoria and hepatitis C genotypes 1 and 3 predominate. Access to hepatitis C care for PWI...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985434/ https://www.ncbi.nlm.nih.gov/pubmed/36870990 http://dx.doi.org/10.1186/s12954-023-00759-0 |
_version_ | 1784900955346567168 |
---|---|
author | Saayman, Elaine Hechter, Vanessa Kayuni, Ndoliwe Sonderup, Mark W. |
author_facet | Saayman, Elaine Hechter, Vanessa Kayuni, Ndoliwe Sonderup, Mark W. |
author_sort | Saayman, Elaine |
collection | PubMed |
description | BACKGROUND: Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PWID is high. It is almost 84% in Pretoria and hepatitis C genotypes 1 and 3 predominate. Access to hepatitis C care for PWID is inadequate given low referral rates, socio-structural barriers, homelessness and limited access to harm reduction. Traditional care models do not address the needs of this population. We piloted a simplified complete point-of-service care model, a first of its kind in the country and sub-continental region. METHODS: Community-based recruitment from Pretoria’s PWID population occurred over 11 months. Participants were screened with point-of-care rapid diagnostic tests for HBsAg (Alere Determine™), hepatitis C and HIV antibodies (OraQuick®). Qualitative HCV viremia was confirmed on site with Genedrive® (Sysmex), similarly at week 4, end of treatment and to confirm sustained virological response. Viremic hepatitis C participants were initiated on 12 weeks of daily sofosbuvir and daclatasvir. Harm reduction and adherence support, through directly observed therapy, peer support, a stipend and transport, was provided. RESULTS: A total of 163 participants were screened for hepatitis C antibody, and 66% were positive with 80 (87%) viremic. An additional 36 confirmed hepatitis C viremic participants were referred. Of those eligible to initiate treatment, 87 (93%) were commenced on sofosbuvir and daclatasvir, with 98% (n = 85) male, 35% (n = 30) HIV co-infected, 1% (n = 1) HBV co-infected and 5% (n = 4) HIV/HBV/HCV triple infected. Some 67% (n = 58) accessed harm reduction packs, 57% (n = 50) opioid substitution therapy and 18% (n = 16) stopped injecting. A per protocol sustained virological response of 90% (n = 51) was achieved with 14% (n = 7) confirmed reinfections following a sustained virological response. HCV RNA qualitative testing performance was acceptable with all sustained virological responses validated against a laboratory assay. Mild adverse effects were reported in 6% (n = 5). Thirty-eight percent (n = 33) of participants were lost to follow-up. CONCLUSION: In our setting, a simplified point-of-service hepatitis C care model for PWID yielded an acceptable sustained virological response rate. Retention in care and follow-up remains both challenging and central to success. We have demonstrated the utility of a model of care for our country and region to utilize this more community acceptable and simplified practice. |
format | Online Article Text |
id | pubmed-9985434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99854342023-03-06 A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa Saayman, Elaine Hechter, Vanessa Kayuni, Ndoliwe Sonderup, Mark W. Harm Reduct J Research BACKGROUND: Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PWID is high. It is almost 84% in Pretoria and hepatitis C genotypes 1 and 3 predominate. Access to hepatitis C care for PWID is inadequate given low referral rates, socio-structural barriers, homelessness and limited access to harm reduction. Traditional care models do not address the needs of this population. We piloted a simplified complete point-of-service care model, a first of its kind in the country and sub-continental region. METHODS: Community-based recruitment from Pretoria’s PWID population occurred over 11 months. Participants were screened with point-of-care rapid diagnostic tests for HBsAg (Alere Determine™), hepatitis C and HIV antibodies (OraQuick®). Qualitative HCV viremia was confirmed on site with Genedrive® (Sysmex), similarly at week 4, end of treatment and to confirm sustained virological response. Viremic hepatitis C participants were initiated on 12 weeks of daily sofosbuvir and daclatasvir. Harm reduction and adherence support, through directly observed therapy, peer support, a stipend and transport, was provided. RESULTS: A total of 163 participants were screened for hepatitis C antibody, and 66% were positive with 80 (87%) viremic. An additional 36 confirmed hepatitis C viremic participants were referred. Of those eligible to initiate treatment, 87 (93%) were commenced on sofosbuvir and daclatasvir, with 98% (n = 85) male, 35% (n = 30) HIV co-infected, 1% (n = 1) HBV co-infected and 5% (n = 4) HIV/HBV/HCV triple infected. Some 67% (n = 58) accessed harm reduction packs, 57% (n = 50) opioid substitution therapy and 18% (n = 16) stopped injecting. A per protocol sustained virological response of 90% (n = 51) was achieved with 14% (n = 7) confirmed reinfections following a sustained virological response. HCV RNA qualitative testing performance was acceptable with all sustained virological responses validated against a laboratory assay. Mild adverse effects were reported in 6% (n = 5). Thirty-eight percent (n = 33) of participants were lost to follow-up. CONCLUSION: In our setting, a simplified point-of-service hepatitis C care model for PWID yielded an acceptable sustained virological response rate. Retention in care and follow-up remains both challenging and central to success. We have demonstrated the utility of a model of care for our country and region to utilize this more community acceptable and simplified practice. BioMed Central 2023-03-04 /pmc/articles/PMC9985434/ /pubmed/36870990 http://dx.doi.org/10.1186/s12954-023-00759-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Saayman, Elaine Hechter, Vanessa Kayuni, Ndoliwe Sonderup, Mark W. A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa |
title | A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa |
title_full | A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa |
title_fullStr | A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa |
title_full_unstemmed | A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa |
title_short | A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa |
title_sort | simplified point-of-service model for hepatitis c in people who inject drugs in south africa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985434/ https://www.ncbi.nlm.nih.gov/pubmed/36870990 http://dx.doi.org/10.1186/s12954-023-00759-0 |
work_keys_str_mv | AT saaymanelaine asimplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica AT hechtervanessa asimplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica AT kayunindoliwe asimplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica AT sonderupmarkw asimplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica AT saaymanelaine simplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica AT hechtervanessa simplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica AT kayunindoliwe simplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica AT sonderupmarkw simplifiedpointofservicemodelforhepatitiscinpeoplewhoinjectdrugsinsouthafrica |